Microencapsulation Of Antibiotic Rifampicin In Poly(3-hydroxybutyrate-co-3- Hydroxyvalerate)

The aim of this study was the preparation of microparticles containing rifampicin using a biodegradable polymer poly(3-hydroxybutyrate-co-3- hydroxyvalerate) for oral administration produced by a bacteria. The poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microparticles with and without rifampicin were prepared by the emulsification and solvent evaporation method, in which chloroform and polyvinyl alcohol are used as the solvent and emulsifier, respectively. Microparticles were obtained within a size range of 20-60 μm by changing the initial poly(3-hydroxybutyrate-co-3-hydroxyvalerate) , polyvinyl alcohol and rifampicin concentrations. An encapsulation efficiency value of 14% was obtained. The optimized total yield of 60% of the poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/ rifampicin was obtained. A load of 0.035 mg/1 mg of PHBV was reached. Almost 90% of the drug loaded in the microparticles was released after 24 h. The size, encapsulation efficiency and ribampicin release of the microparticles varied as a function of the initial poly(3-hydroxybutyrate-co-3-hydroxyvalerate), polyvinyl alcohol and rifampicin concentrations. It was demonstrated that the microencapsulated rifampicin, although was not totally available in the medium, exhibited a similar inhibition value as free rifampicin at 24 h of incubation with S. aureus. Cytotoxicity assays demonstrated a reduction of the toxicity when rifampicin was microencapsulated in poly(3-hydroxybutyrate-co-3-hydroxyvalerate) while maintaining its antibacterial activity. © 2008 The Pharmaceutical Society of Korea.311115091516Anisimova, Y.V., Gelperina, S.I., Peloquim, C.A., Heifets, L.B., Nanoparticles as antituberculosis drugs carriers: Effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. (2000) J. Nanoparticle. Res., 2, pp. 165-171Bianchi, V., Fortunati, E., Cellular effects of an anionic surfactant detected in V79 fibroblasts by different cytotoxicity tests (1990) Toxicol in Vitro, 4, pp. 9-16Borefreund, E., Puerner, J.A., A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR 90) (1984) J. Tissue Cult. Methods, 9, pp. 7-9Borin, A., Ferrão, M.F., Mello, C., Cordi, L., Pataca, L.C.M., Durán, N., Poppi, R.J., Quantification of Lactobacillus in fermented milk by multivariate image analysis with least-squares support-vector machines (2007) Anal. Bioanal. Chem., 387, pp. 1105-1112Campbel, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., Darst, S.A., Structural mechanism for rifampicin inhibition of bacterial RNA polymerase (2001) Cell, 104, pp. 901-912Coimbra, P.A., De Sousa, H.C., Gil, M.H., Preparation and characterization of flurbiprofen-loaded poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres (2008) J. Microencapsul., 25, pp. 170-178Celikkaya, E., Denkbas, E.B., Piskin, E., Rifampicin carrying poly (D,L-lactide)/poly(ethylene glycol) microspheres: Loading and release (1996) Artif. Organs, 20, pp. 743-751Chen, J., Davis, S.S., The release of diazepam from poly(hydroxybutyrate-co-hydroxyvalerate) microspheres (2002) J Microencapsul, 19, pp. 191-201Cingi, M.R., De Angelis, I., Fortunati, E., Reggiani, D., Bianchi, V., Tiozzo, R., Zucco, F., Choice and standardization of test protocols in cytotoxicology: A multicentre approach (1991) Toxicol in Vitro, 5, pp. 119-125Coccoli, V., Luciani, A., Orsi, S., Guarino, V., Causa, F., Netti, P.A., Engineering of poly(e-caprolactone) microcarriers to modulate protein encapsulation capability and release kinetic (2008) J. Mater. Sci. Mater. Med., 19, pp. 1703-1711Corrêa, D.H.A., Melo, P.S., Carvalho, C.A.A., De Azevedo, M.B.M., Durán, N., Haun, M., Dehydrocrotonin and its β-cyclodextrin complex: Cytotoxicity in V79 fibroblasts and rat cultured hepatocytes (2005) Eur. J. Pharmacol., 510, pp. 17-24Dang, M.H., Birchler, F., Wirtermantel, E., Toxicity screening of biodegradable polymers 2 Evaluation of cell culture test with medium extract (1997) J. Environ. Polym. Degrad., 5, pp. 49-56Denizot, F., Lang, R., Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability (1986) J. Immunol. Methods, 89, pp. 271-277Durán, N., De Oliveira, A., De Azevedo, M.M.M., In vitro studies on the release of isoniazid incorporated in poly (epsilon-caprolactone) (2006) J. Chemother., 18, pp. 473-479Durán, N., Marcato, P.D., Buffo, C.M.S., De Azevedo, M.M.M., Esposito, E., Poly(epsilon-caprolactone)/propolis extract: Microencapsulation and antibacterial activity evaluation (2007) Pharmazie, 62, pp. 287-290Esmaeili, F., Hosseini-Nasr, M.-H., Rad-Malekshahi, M., Samadi, N., Atyabi, F., Dinarvand, R., Preparation and antibacterial activity evaluation of rifampicin-loaded poly (lactideco-glycolide) nanoparticles (2007) Nanomedicine: NBM., 3, pp. 161-167Fumori, I., Makino, K., Preparation and properties of monodispersed rifampicin-loaded poly(lactide-co-glycolide) microspheres (2004) Colloid Surf. B. Biointerfaces, 39, pp. 17-21Gogolewski, S., Jovanivich, M., Perren, M., Dillon, J.G., Hughes, M.K., The effect of melt-processing on the degradation of selected polyhydroacids, polylactide, polyhydroxybutyrate and poly(hydroxybutyrate-co- hydroxyvalerate) (1993) J. Biomed. Mater. Res., 27, pp. 1135-1148Govender, T., Stolnik, S., Garnett, M.C., Illum, S., Davis, S.S., PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug (1999) J. Control. Release, 57, pp. 171-185Harma, R., Saxena, D., Dwivedi, A.K., Misra, A., Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis (2001) Pharm. Res., 18, pp. 1405-1410Kamath, M.P., Shenoy, B.D., Tiwari, S.B., Karki, R., Udupa, N., Kotian, M., Prolonged release biodegradable vesicular carriers for rifampicin-formulation and kinetics of release (2000) Indian J. Exp. Biol., 38, pp. 113-138Kassab, A.C., Xu, K., Denkbas, E.B., Dou, Y., Zhao, S., Piskin, E., Rifampicin carrying polyhydroxybutyrate microspheres as a potential chemoembolizant agent (1997) J. Biomater. Sci. Polym., 8, pp. 947-961Labana, S., Pandey, R., Sharma, S., Khuller, G.K., Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes (2002) Int. J. Antimicrob. Agents, 20, pp. 301-304Marcato, P.D., Duran, N., New aspects of nanopharmaceutical delivery systems (2008) J. Nanosci. Nanotechnol., 8, pp. 2216-2229Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G.K., Prasad, B., Poly (DL-lactide-co-glycolide) nanoparticlebased inhalable sustained drug delivery system for experimental tuberculosis (2003) J. Antimicrob. Chemother., 52, pp. 981-986Pandey, R., Sharma, S., Khuller, G.K., Oral solid lipid nanoparticle-based antitubercular chemotherapy (2005) Tuberculosis, 85, pp. 415-420Pandey, R., Sharma, S., Khuller, G.K., Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs (2006) Drug Delivery, 13, pp. 287-294Pandey, R., Sharma, S., Khuller, G.K., Oral poly(lactideco-glycolide) nanoparticle based antituberculosis drug delivery: Toxicological and chemotherapeutic implications (2006) Indian J. Exper. Biol., 44, pp. 459-467Petrelli, D., Repetto, A., D'Ercole, S., Rombini, S., Ripa, S., Prenna, M., Vitali, L.A., Analysis of meticillin-susceptible and meticillinresistant biofilm-forming Staphylococcus aureus from catheter infections isolated in a large Italian hospital (2008) J. Med. Microbiol., 57, pp. 364-372Pich, A., Schiemenz, N., Corten, C., Adler, H.J.P., Preparation of poly(3hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) particles in O/W emulsion (2006) Polymer, 47, pp. 1912-1920Sendil, A., Gursel, I., Wise, D.L., Hasirci, V., Antibiotic release from biodegradable PHBV microparticles (1999) J. Control. Release, 59, pp. 207-217Schaffazick, S.R., Guterres, S.S.U., Freitas, L.D., Pohlmann, A.R., Physicochemical characterization and stability of the polymeric nanoparticle systems for drug administration (2003) Quim Nova, 26, pp. 726-737Sharma, R., Muttil, P., Yadav, A.B., Rath, S.K., Bajpai, V.B., Mani, U., Misra, A., Uptake of inhalable microparticles affects defense responses of macrophages infected with Mycobacterium tuberculosis H37Ra (2007) J. Antimicrob. Chemother., 59, pp. 499-506Takenaga, M., Ohta, Y., Tokura, Y., Hamaguchi, A., Igarashi, R., Disratthakit, A., Doi, N., Lipid microsphere formulation containing rifampicin targets alveolar macrophages (2008) Drug Delivery., 15, pp. 169-175Tomoda, K., Makino, K., Effects of lung surfactants on rifampicin release rate from monodisperse rifampicinloaded PLGA microspheres (2007) Colloids Surf. B: Biointerfaces, 55, pp. 115-124Tomoda, K., Kojima, S., Kajimoto, M., Watanabe, D., Nakajima, T., Makino, K., Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres (2005) Colloids Surf. B: Biointerfaces, 45, pp. 1-6Ul-Ain, Q., Sharma, S., Khuller, G.K., Garg, S.K., Alginate-based oral drug delivery system for tuberculosis: Pharmacokinetics and therapeutic effects (2003) J. Antimicrob. Chemother., 51, pp. 931-938Zahoor, A., Sharma, S., Khuller, G.K., Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis (2005) Inter. J. Antimicrob. Agents, 26, pp. 298-303Zahoor, A., Sharma, S., Khuller, G.K., Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis (2007) Nanomedicine: NBM., 3, pp. 239-24